|
Oct 9
|
Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ...
|
|
Jul 24
|
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
|
|
Jul 9
|
Immunic Appoints Jason Tardio as Chief Operating Officer and President
|
|
May 9
|
Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript
|
|
May 9
|
We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully
|
|
May 8
|
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 1
|
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
|
|
May 1
|
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
|
|
Apr 30
|
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
|
|
Apr 29
|
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
|
|
Apr 4
|
With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors
|
|
Apr 4
|
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
|
|
Mar 21
|
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
|
|
Mar 21
|
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
|
|
Mar 20
|
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
|
|
Mar 8
|
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
|
|
Mar 7
|
Immunic to Participate in Investor and Scientific Conferences in March
|
|
Jan 5
|
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
|
|
Jan 5
|
Immunic, Inc. Announces Private Placement of up to $240 Million
|
|
Nov 7
|
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
|